Amr-free microbial expression hosts for industrial protein production
BRAIN Biotech offers AMR-free microbial strains for industrial protein production using Bacillus subtilis, Pichia pastoris, and Aspergillus niger. These strains enable high-yield production without antimicrobial resistance concerns, supported by advanced CRISPR technology.
Overview
BRAIN Biotech presents three advanced antimicrobial resistance (AMR)-free microbial expression hosts for industrial protein production: Bacillus subtilis, Pichia pastoris, and Aspergillus niger. These platforms offer a robust solution for producing proteins without the risks associated with traditional AMR methods. The strains are designed for high-yield production, utilizing genomic integration of expression cassettes. BRAIN Biotech's expertise ensures a seamless transition from strain selection to up-scaling and production.
Technical specifications
- Strains offered: Bacillus subtilis, Pichia pastoris (Komagataella phaffii), and Aspergillus niger.
- Genetic modification methods: Classical methods and proprietary CRISPR technology for precise genome editing.
- Integration capabilities: Genomic integration of expression cassettes, with options for random or site-specific integration.
- Production scale: Up-scaling capabilities to 200L at BRAIN Zwingenberg and 10,000L at Biocatalysts UK.
- Media: Animal-free, defined media with no BSE/TSE risk.
- Customization: Tailored production strains for specific proteins, with options for methanol-free systems in P. pastoris.
Technology readiness level
This technology is at a readiness level of 8, indicating that it has been demonstrated in operational settings and is ready for commercial deployment. BRAIN Biotech offers comprehensive support for strain development, optimization, and production scaling, ensuring economic feasibility and high success rates.
About BRAIN Biotech AG
BRAIN Biotech AG is an integrated industrial biotechnology company that develops, produces, and distributes specialty enzymes, proteins, and microbial production strains. The company operates through two main business segments: BRAINBiocatalysts, which focuses on the commercialization of enzymes and specialty ingredients, and BRAINBioIncubator, which conducts research-intensive development projects. Utilizing advanced expertise in biology, bioinformatics, and bioprocess engineering, the company provides end-to-end services ranging from discovery and strain development to large-scale fermentation and manufacturing. They function as a partner for industries including food and beverage, life sciences, and chemical sectors, delivering solutions that aim to enhance industrial sustainability and efficiency.
By leveraging their proprietary technology portfolio and R&D capabilities, BRAIN Biotech enables customers to optimize production processes and develop more sustainable bio-based products. With over 30 years of experience, the company serves as an innovation partner that helps clients navigate complex development challenges, from laboratory-scale concepts to commercial-scale production. Their work directly addresses global sustainability goals by providing biological alternatives for traditional industrial methods. The group operates international facilities across Europe and the USA, providing a robust infrastructure to support long-term development partnerships and the monetization of biotechnological intellectual property.
Inquire about this partnering listing
Industry applications
delivered to your inbox.